- Joined
- Aug 9, 2013
- Messages
- 102
- Reaction score
- 1
I read that Amgen terminated their phase 3 study of talimogene laherparepvec for SCC. They said it was due to the role HPV plays in the oncogenesis of H&N cancer.
Yes, a mandatory Gardasil vaccination would be wonderful to hopefully prevent new cases, but what do you do with all the current ones?
I absolutely hate it when companies stop trials for this...phase 3 trials should only be stopped for a) ineffectiveness or b) high rate of severe ADRs.
T-VEC had an awesome response rate and tolerable side-effects for use in SCC. http://meetinglibrary.asco.org/content/34768-65
Intratumoral injection of T-VEC to treat the gross neoplasms, and pre-targeted alpha RIT to treat any remaining micrometases.
Yes, a mandatory Gardasil vaccination would be wonderful to hopefully prevent new cases, but what do you do with all the current ones?
I absolutely hate it when companies stop trials for this...phase 3 trials should only be stopped for a) ineffectiveness or b) high rate of severe ADRs.
T-VEC had an awesome response rate and tolerable side-effects for use in SCC. http://meetinglibrary.asco.org/content/34768-65
Intratumoral injection of T-VEC to treat the gross neoplasms, and pre-targeted alpha RIT to treat any remaining micrometases.
